NCT07262229

Brief Summary

The goal of this pilot randomized controlled trial is to evaluate the feasibility, acceptability, and preliminary effects of a theory-based self-management digital intervention (Respir'air BPCO) designed to promote physical activity in patients with Chronic Obstructive Pulmonary Disease (COPD) after completion of a pulmonary rehabilitation program. The main question it aims to answer is: Is the Respir'air BPCO intervention (mobile app) feasible, acceptable, and preliminarily effective in increasing physical activity, enhancing self-management, improving motivation, and quality of life, while reducing dyspnea severity, exacerbations, and hospitalizations, compared with no additional intervention? Researchers will compare an experimental group (receiving the Respir'air BPCO intervention + usual care) to a control group (no additional intervention, only usual care) Participants will: Be assigned either to the control group, receiving no additional intervention beyond usual care (traditional pulmonologist follow-up), or to the experimental group, receiving access to the Respir'air BPCO mobile app in addition to usual care.

  • Complete baseline assessments immediately after finishing their in-person pulmonary rehabilitation program.
  • Complete follow-up assessments at 3 months and 6 months after the start of the intervention

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
2mo left

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Jan 2026Sep 2026

First Submitted

Initial submission to the registry

November 17, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 3, 2025

Completed
29 days until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

December 3, 2025

Status Verified

November 1, 2025

Enrollment Period

2 months

First QC Date

November 17, 2025

Last Update Submit

November 21, 2025

Conditions

Keywords

self-managementCOPDeHealthdigital intervention

Outcome Measures

Primary Outcomes (10)

  • Feasibility - Time required to complete recruitment

    T0 - End of face-to-face PR program (Researchers expect to need 3 months to recruit 50 participants.)

  • Feasibility - The amount of missing data in the completed questionnaires

    T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Feasibility - Potential refinements after the completion of the pilot study

    A digital logbook for researchers' use, to record any observations or comments (patients and/or researchers perspectives) regarding the intervention design, content and/or usage, with the aim of informing potential refinements after the completion of the pilot study

    From the start of the intervention to study completion, assessed for up to 9 months.

  • Feasibility - Number of technical problems auto reported by the patient

    T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Feasibility - Intervention fidelity

    Exposure rate to all content available within the mobile application

    T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Acceptability - Consent and retention rates

    Consent rate: proportion of eligible participants who sign the informed consent form Retention rate: proportion of enrolled participants who remain in the study until the final assessment point

    T -1: 1 week before completion of the face-to-face PR program (±72 hours)

  • Acceptability - Acceptance rate of the allocated group

    Acceptance rate will be assessed using administrative study records. It will be defined as the proportion of enrolled participants who agree to participate in the group to which they were allocated (control or intervention) immediately after randomization.

    T -1: 1 week before completion of the face-to-face PR program (±72 hours)

  • Acceptability - Rate of participants successfully recruited

    T0: Within 72 hours after completion of the face-to-face PR program

  • Acceptability - Intervention acceptance

    Daily App Login Status

    T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Acceptability - Intervention acceptance

    French-adapted version of the Treatment Acceptance and Preference (TAP) questionnaire.Responses are scored on a five-point Likert scale ranging from 0 ("not at all") to 4 ("extremely"), with higher scores reflecting greater acceptance.

    T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

Secondary Outcomes (7)

  • Preliminary effectiveness measures - Main variable: number of daily steps

    T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Preliminary effectiveness measures - secondary variable: Self-management

    T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Preliminary effectiveness measures - secondary variable: Motivational regulation of physical activity

    T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Preliminary effectiveness measures - secondary variable: Health-related quality of life

    T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • Preliminary effectiveness measures - secondary variable: severity of dyspnea

    T0: Within 72 hours after completion of the face-to-face PR program T1: 3 months after the start of the intervention (±1 week) T2: 6 months after the start of the intervention (±1 week)

  • +2 more secondary outcomes

Study Arms (2)

Usual Care

NO INTERVENTION

Traditional pulmonologist follow-up, along with physiotherapy sessions

Respir'air BPCO

EXPERIMENTAL

Self-management digital intervention (Respir'air BPCO)

Behavioral: Respir'air BPCO

Interventions

Respir'air BPCOBEHAVIORAL

Self-management digital intervention (Respir'air BPCO) grounded in theory (Self-Care Theory of Chronic Illness, Self-Determination Theory of Human Motivation, and the Behavior Change Techniques taxonomy). The mobile application includes educational resources (text, video, images), examples of physical activities (walking, etc), environmental data (air quality), a personal activity log (daily steps), reminders and motivational messages.

Respir'air BPCO

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • a GOLD COPD diagnosis stage 1 to 4, classification B or E;
  • admitted electively at Hospital for PR;
  • had completed the pulmonary rehabilitation program;
  • age over 18 years;
  • ability to provide informed consent;
  • internet access;
  • ownership of a smartphone or tablet;
  • self-assessed perceived ease of use of digital devices.

You may not qualify if:

  • clinical instability confirmed by the team of healthcare professionals;
  • severe cardiovascular disease confirmed by medical diagnosis;
  • recent history of neoplasia or autoimmune disease; other physical activity-limiting clinical condition confirmed by medical diagnosis (e.g. neurological disease);
  • other respiratory disease as primary diagnosis; e) inability to read, understand or speak French;
  • f) cognitive impairment diagnosed by the medical team.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pôle de pneumologie de l'Hôpital de Rolle

Rolle, Switzerland

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ricardo Salgado, MSc

    Institut et Haute Ecole de la Santé la Source

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ricardo Salgado, MSc

CONTACT

Philippe Delmas, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Lecturer UAS

Study Record Dates

First Submitted

November 17, 2025

First Posted

December 3, 2025

Study Start

January 1, 2026

Primary Completion

March 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

December 3, 2025

Record last verified: 2025-11

Locations